Venture cash funds first human trials
Private company trial initiations stand out in the latest week’s disclosures.
Pfizer shuffles its deck post-Seagen
The group’s B7-H4-targeting bispecific is out, in favour of Seagen’s ADC.
Private company trial initiations stand out in the latest week’s disclosures.
The group’s B7-H4-targeting bispecific is out, in favour of Seagen’s ADC.
